Search

Displaying results 9121 - 9130 of 10000 in total
  1. Drug

    Renzapride

    go.drugbank.com/drugs/DB04917
    Investigational

    Renzapride is currently in Phase III clinical development in the United States for the treatment of constipation-predominant irritable bowel syndrome (IBS-C). It has been suggested that renzapride is effective in the treatment of irritab...

  2. Drug

    Tamibarotene

    go.drugbank.com/drugs/DB04942
    Investigational

    Tamibarotene is a novel synthetic retinoid for acute promyelocytic leukaemia (APL).

  3. Drug

    XL784

    go.drugbank.com/drugs/DB04991
    Investigational

    XL784 is a potent inhibitor of the ADAM-10 metalloprotease enzyme, a target of significant interest because of its important role in blood vessel formation and cell proliferation.

  4. Drug

    XEN-2174

    go.drugbank.com/drugs/DB05012
    Experimental

    XEN-2174 is a synthetic drug modeled on a peptide from the venom of a cone shell found on Australia's Great Barrier Reef. … XEN-2174 represents a new class of molecules, called the chi conopeptides that selectively inhibit the Norepinephrine Transporter (NET).

  5. Drug

    YSIL6

    go.drugbank.com/drugs/DB05017
    Experimental

    YSIL6 is a small-molecule drug in development for the treatment of inflammatory diseases, including rheumatoid arthritis and psoriasis.

  6. Drug

    SLV319

    go.drugbank.com/drugs/DB05077
    Experimental

    SLV319 belongs to a novel class of agents called CB1 antagonists, which work by blocking the cannabinoid type 1 (CB1) receptor.

  7. Drug

    HY10275

    go.drugbank.com/drugs/DB05079
    Experimental

    HY10275 is a novel compound specifically designed to modulate two key neurobiological mechanisms that interfere with the sleeping process.

  8. Drug

    FP0011

    go.drugbank.com/drugs/DB05090
    Experimental

    FP0011 is a small molecule antiglutamatergic compound with symptomatic and disease modifying effects in a variety of neurological disorders (amyotrophic lateral sclerosis and Parkinson's disease).

  9. Drug

    XL228

    go.drugbank.com/drugs/DB05184
    Investigational

    XL228 is a novel anticancer compound designed to inhibit the insulin-like growth factor type-1 receptor (IGF1R), Src and Abl tyrosine kinases – targets that play crucial roles in cancer cell proliferation

  10. Drug

    XL281

    go.drugbank.com/drugs/DB05190
    Investigational

    XL281 is a novel anticancer compound designed to potently inhibit the RAS/RAF/MEK/ERK signaling pathway. … XL281 is a specific inhibitor of RAF kinases, including the mutant form of B-RAF, which is activated in 60 percent of melanomas, 24-44 percent of thyroid cancers, and 9 percent of colon cancers.